EFFICACY AND SAFETY OF CHROMIUM AS A THERAPEUTIC INTERVENTION

该子项目是利用 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得主要资金， 因此可以在其他CRISP条目中表示。列出的机构是 中心，不一定是研究者的机构。 肥胖的程度已经达到流行病的比例[1]，并导致死亡率和发病率增加[2]。 死亡率和发病率的一部分是由于胰岛素抵抗和糖尿病发病率的增加。 然而，它可以防止糖尿病的进展。 最近的一项研究表明，当患有胰岛素抵抗的患者在糖尿病发展之前接受治疗时，继续发展糖尿病的受试者数量急剧减少[3]。 尽管几种常规药物可有效治疗与2型糖尿病相关的胰岛素抵抗，但膳食补充剂吡啶甲酸铬也已被证明可改善2型糖尿病患者的胰岛素敏感性[4]。 有趣的是，铬相对便宜，而且显然耐受性良好[4]。 本提案的具体目标1将检查补充吡啶甲酸铬治疗肥胖相关胰岛素抵抗的安全性和有效性。 我们将在一项为期两个月的治疗过程中进行安慰剂对照研究，评估铬补充剂对胰岛素敏感性的改善。 我们还将评估吡啶甲酸铬治疗的安全性。 将监测肝、肾功能和氧化损伤的参数，以确定是否存在可能的铬相关毒性。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The level of obesity has reached epidemic proportions [1] and contributes to increased mortality and morbidity [2]. Part of both mortality and morbidity arises from an increased incidence of insulin resistance and diabetes. However, it is possible to prevent progression to diabetes. A recent study has shown that when patients with insulin resistance were treated prior to the development of diabetes, there was a dramatic decrease in the number of subjects who went on to develop the disease [3]. Although several conventional drugs are effective in treating the insulin resistance associated with type 2 diabetes mellitus, the dietary supplement chromium picolinate has also been shown to improve insulin sensitivity in patients with type 2 diabetes mellitus[4]. Intriguingly, chromium is comparatively inexpensive and apparently well-tolerated [4]. Specific Aim 1 of this proposal will examine the safety and efficacy of supplemental chromium picolinate in the treatment of insulin resistance in obesity-related insulin resistance. We will assess improvements in insulin sensitivity in a placebo-controlled study of chromium supplementation over a two-month course of therapy. We will also assess the safety of chromium picolinate treatment. Parameters of liver, renal function and oxidative damage will be monitored for possible chromium-related toxicities.